Mechanisms of action of formononetin, an extract from Astragalus membranaceus medicinal plant, in ameliorating Alzheimer’s disease

Abstract

Alzheimer’s disease (AD), the term “dementia”, describes a specific neuropathology together with the development and progression of age-related cognitive and functional loss. Formononetin is naturally occurring isoflavone recognized for its potential health benefits, anti-oxidant, anti-inflammatory, anti-cancer, and anti-apoptotic properties. Neurodegenerative disorders arise from the gradual loss of function and eventual death of nerve cells in the brain or peripheral nervous system. Astragalus membranaceus is a traditional plant with a variety of pharmacological and biochemical properties, including antiviral, anti-hyperglycaemic, and immunomodulatory effects. Moreover, the expression of membrane-bound and soluble receptor for advanced glycation end products (RAGE) is enhanced in the AD brain due to increased levels of soluble and insoluble amyloid-beta (Aβ) peptides. Additionally, in inflammatory circumstances, leukocytes’ firm attachment and transmigration to endothelial cells are regulated by intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). Formononetin also possesses anti-bacterial, anti-inflammatory, anti-cancer, anti-oxidant, and estrogenic activity. Formononetin has emerged as a promising agent in the modulation of mediators involved in neurodegenerative disease. Formononetin might modulate nuclear factor erythroid 2-related factor 2 (Nrf-2) signaling pathway to potentiate the anti-Alzheimer’s activity. Additionally, formononetin might inhibit the Aβ/RAGE interaction which further inactivates the activity of extracellular signal regulated kinase (ERK), Janus kinase (JNK) signaling pathway that results in the reduction of nuclear translocation of nuclear factor kappa B (NF-κB) and also reduces the cytokines level to ameliorate AD. It might inhibit the ICAM, VCAM, and THP-1 proteins. Therefore, this compound offers potential therapeutic benefits by reducing cytokine levels to ameliorate AD. This review article is designed to explore the mechanistic interplay underlying the anti-Alzheimer’s effect of A. membranaceus, especially formononetin.

Keywords

Introduction / formononetin / Nrf-2 / Aβ/RAGE / ICAM & VCAM / Alzheimer’s disease

References

[1] Davenport F,Gallacher J,Kourtzi Z,Koychev I,Matthews PM,Oxtoby NP,et al.Neurodegenerative disease of the brain: a survey of interdisciplinary approaches.J R Soc Interface.2023;20:20220406.

[2] Ramachandran AK,Das S,Joseph A,Shenoy GG,Alex AT,Mudgal J.Neurodegenerative Pathways in Alzheimer’s Disease: A Review.Curr Neuropharmacol.2021;19:679-92.

[3] Crous-Bou M,Minguillón C,Gramunt N,Molinuevo JL.Alzheimer’s disease prevention: from risk factors to early intervention.Alzheimers Res Ther.2017;9:71.

[4] Janoutová J,Kovalová M,Machaczka O,Ambroz P,Zatloukalová A,Němček K,et al.Risk Factors for Alzheimer’s Disease: An Epidemiological Study.Curr Alzheimer Res.2021;18:372-9.

[5] 2024 Alzheimer’s disease facts and figures.Alzheimers Dement.2024;20:3708-821.

[6] Salminen A,Ojala J,Kauppinen A,Kaarniranta K,Suuronen T.Inflammation in Alzheimer’s disease: amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors.Prog Neurobiol.2009;87:181-94.

[7] Khan S,Barve KH,Kumar MS.Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease.Curr Neuropharmacol.2020;18:1106-25.

[8] McNaull BB,Todd S,McGuinness B,Passmore AP.Inflammation and anti-inflammatory strategies for Alzheimer’s disease – a mini-review.Gerontology.2010;56:3-14.

[9] Deane R,Sagare A,Zlokovic BV.The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer’s disease.Curr Pharm Des.2008;14:1601-5.

[10] Yousef H,Czupalla CJ,Lee D,Chen MB,Burke AN,Zera KA,et al.Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1.Nat Med.2019;25:988-1000.

[11] Cheng JJ,Wung BS,Chao YJ,Wang DL.Cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intercellular adhesion molecule-1 expression.Hypertension.1996;28:386-91.

[12] Shah U,Shah A,Patel S,Patel A,Patel M,Solanki N,et al.Atorvastatin’s Reduction of Alzheimer’s Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment.CNS Neurol Disord Drug Targets.2023;22:1462-71.

[13] Shah H,Patel A,Parikh V,Nagani A,Bhimani B,Shah U,et al.The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer’s Disease.CNS Neurol Disord Drug Targets.2020;19:184-94.

[14] Křížová L,Dadáková K,Kašparovská J,Kašparovský T.Isoflavones.Molecules.2019;24:1076.

[15] Tay KC,Tan LT,Chan CK,Hong SL,Chan KG,Yap WH,et al.Formononetin: A Review of Its Anticancer Potentials and Mechanisms.Front Pharmacol.2019;10:820.

[16] Aliya S,Alhammadi M,Park U,Tiwari JN,Lee JH,Han YK,et al.The potential role of formononetin in cancer treatment: An updated review.Biomed Pharmacother.2023;168:115811.

[17] Singh L,Kaur H,Chandra Arya G,Bhatti R.Neuroprotective potential of formononetin, a naturally occurring isoflavone phytoestrogen.Chem Biol Drug Des.2024;103:e14353.

[18] Yu L,Zhang Y,Chen Q,He Y,Zhou H,Wan H,et al.Formononetin protects against inflammation associated with cerebral ischemia-reperfusion injury in rats by targeting the JAK2/STAT3 signaling pathway.Biomed Pharmacother.2022;149:112836.

[19] Machado Dutra J,Espitia PJP,Andrade Batista R.Formononetin: Biological effects and uses – A review.Food Chem.2021;359:129975.

[20] Fan M,Li Z,Hu M,Zhao H,Wang T,Jia Y,et al.Formononetin attenuates Aβ_25-35-induced adhesion molecules in HBMECs via Nrf2 activation.Brain Res Bull.2022;183:162-71.

[21] Fei HX,Zhang YB,Liu T,Zhang XJ,Wu SL.Neuroprotective effect of formononetin in ameliorating learning and memory impairment in mouse model of Alzheimer’s disease.Biosci Biotechnol Biochem.2018;82:57-64.

[22] Sun M,Zhou T,Zhou L,Chen Q,Yu Y,Yang H,et al.Formononetin protects neurons against hypoxia-induced cytotoxicity through upregulation of ADAM10 and sAβPPα.J Alzheimers Dis.2012;28:795-808.

[23] Hu P,SurigugaZhao M,Chen S,Wu X,Wan Q.Transcriptional regulation mechanism of flavonoids biosynthesis gene during fruit development in astragalus membranaceus.Front Genet.2022;13:972990.

[24] Li Y,Wang J,Li L,Song W,Li M,Hua X,et al.Natural products of pentacyclic triterpenoids: from discovery to heterologous biosynthesis.Nat Prod Rep.2023;40:1303-53.

[25] Wang S,Li J,Huang H,Gao W,Zhuang C,Li B,et al.Anti-hepatitis B virus activities of astragaloside IV isolated from Radix Astragali.Biol Pharm Bull.2009;32:132-5.

[26] Li S,Qi Y,Ren D,Qu D,Sun Y.The Structure Features and Improving Effects of Polysaccharide from Astragalus membranaceus on Antibiotic-Associated Diarrhea.Antibiotics (Basel).2020;9:8.

[27] Liu P,Zhao H,Luo Y.Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic.Aging Dis.2017;8:868-86.

[28] Peng Y,Deng X,Yang SS,Nie W,Tang YD.Progress in Mechanism of Astragalus membranaceus and Its Chemical Constituents on Multiple Sclerosis.Chin J Integr Med.2023;29:89-95.

[29] Cheng Y,Lin L,Huang P,Zhang J,Pan X.Efficacy, safety, and response predictors of Astragalus in patients with mild to moderate Alzheimer’s disease: A study protocol of an assessor-blind, statistician-blind open-label randomized controlled trial.Contemp Clin Trials Commun.2024;41:101339.

[30] Dong M,Li J,Yang D,Li M,Wei J.Biosynthesis and Pharmacological Activities of Flavonoids, Triterpene Saponins and Polysaccharides Derived from Astragalus membranaceus.Molecules.2023;28:5018.

[31] Singh A,Singh L.Acyclic sesquiterpenes nerolidol and farnesol: mechanistic insights into their neuroprotective potential.Pharmacol Rep.2025;77:31-42.

[32] Kaczmarczyk-Sedlak I,Wojnar W,Zych M,Ozimina-Kamińska E,Taranowicz J,Siwek A.Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis.Evid Based Complement Alternat Med.2013;2013:457052.

[33] Singh A,Kabra A,Singh L.Role of Formononetin (Isoflavone) in Parkinson’s Disease.Lett Appl NanoBiosci.2025;14:72.

[34] Tian J,Wang XQ,Tian Z.Focusing on Formononetin: Recent Perspectives for its Neuroprotective Potentials.Front Pharmacol.2022;13:905898.

[35] Li G,Yang M,Hao X,Li C,Gao Y,Tao J.Acute toxicity of sodium formononetin-3'-sulphonate (Sul-F) in Sprague-Dawley rats and Beagle dogs.Regul Toxicol Pharmacol.2015;73:629-33.

[36] Pingale TD,Gupta GL.Acute and sub-acute toxicity study reveals no dentrimental effect of formononetin in mice upon repeated i.p. dosing.Toxicol Mech Methods.2023;33:688-97.

[37] Singh SP,WahajuddinTewari D,Pradhan T,Jain GK.PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone.Food Chem Toxicol.2011;49:1056-62.

[38] Luo LY,Fan MX,Zhao HY,Li MX,Wu X,Gao WY.Pharmacokinetics and Bioavailability of the Isoflavones Formononetin and Ononin and Their in Vitro Absorption in Ussing Chamber and Caco-2 Cell Models.J Agric Food Chem.2018;66:2917-24.

[39] Kim JH,Kang DW,Cho SJ,Cho HY.Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations.Pharmaceutics.2023;15:45.

[40] Gao J,Liu ZJ,Chen T,Zhao D.Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali.Pharm Biol.2014;52:1217-22.

[41] Yan SD,Bierhaus A,Nawroth PP,Stern DM.RAGE and Alzheimer’s disease: a progression factor for amyloid-β-induced cellular perturbation?J Alzheimers Dis.2009;16:833-43.

[42] Dalal D,Singh L,Singh A.Mechanistic insight unrevealing the potential of Diadzein in ameliorating the Alzheimer’s disease.Front Health Inf.2024;13:7898-906.